<p>List of Contributors ix</p> <p>Preface xv</p> <p><b>Section I Protein Folding and Quality Control in Drug Discovery 1</b></p> <p>1 Epichaperomes as a Gateway to Understanding, Diagnosing, and Treating Disease Through Rebalancing Protein–Protein Interaction Networks 3<br /><i>Chander S. Digwal, Sahil Sharma, Anand R. Santhaseela, Stephen D. Ginsberg, and Gabriela Chiosis</i></p> <p>2 Stability of Steroid Hormone Receptors: The Intersection of Proteostasis and Selective Degradation 27<br /><i>Zachary J. Gale-Day and Jason E. Gestwicki</i></p> <p>3 Pharmacological Chaperones: Therapeutic Potential for Diseases Resulting from GPCR Misfolding 65<br /><i>Suli-Anne Laurin, Sajjad Ahrari, and Michel Bouvier</i></p> <p><b>Section II Protein Degradation and Clearance as Drug Targeting Opportunities 135</b></p> <p>4 Exploiting the Proteasome for Disease Treatment: From Dynamic Architecture to Vast Functions 137<br /><i>Gwen R. Buel, Xiuxiu Lu, and Kylie J. Walters</i></p> <p>5 Targeting the Ubiquitination Cascade for Drug Discovery 179<br /><i>Qi Liu, Gabriel LaPlante, and Wei Zhang</i></p> <p>6 Understanding, Targeting, and Hijacking Autophagy 227<br /><i>Hongguang Xia, Xiaoyan Xu, Mengxin Zhou, Manke Zhang, and Lingzhi Ye</i></p> <p>7 Deubiquitinating Enzymes: From Undruggable Targets to Emerging Opportunities 249<br /><i>Xiaoxi Liu, Laura Doherty, Alejandra Felix, and Sara Buhrlage</i></p> <p><b>Section III Redirecting Protein Degradation Processes for Drug Development 283</b></p> <p>8 History of IMiDs and Protein Degradation as a Pharmacological Modality 285<br /><i>Junichi Yamamoto, Tomoko Asatsuma-Okumura, Takumi Ito, Yuki Yamaguchi, and Hiroshi Handa</i></p> <p>9 PROTAC Degraders: Mechanism, Recent Advances, and Future Challenges 317<br /><i>Alessio Ciulli and Oliver Hsia</i></p> <p>10 Biochemical Principles of Targeted Protein Degradation 357<br /><i>Roman V. Agafonov, Richard W. Deibler, William A. Elam, Joe S. Patel, and Stewart L. Fisher</i></p> <p>11 Pharmacology of PROTAC Degrader Molecules: Optimizing for In Vivo Performance 385<br /><i>Andy Pike, Sofia Guzzetti, Pablo M. Morentin Gutierrez, and James S. Scott</i></p> <p><b>Section IV Emerging Technologies and Future Opportunities 419</b></p> <p>12 Proximity-Inducing Bifunctional Molecules Beyond PROTACs 421<br /><i>Sophia Lai, Ashley E. Modell, and Amit Choudhary</i></p> <p>13 Strategies for Tag-Based Protein Control 447<br /><i>Behnam Nabet, Nathanael S. Gray, and Fleur M. Ferguson</i></p> <p>14 Targeted Protein Degradation in Antiviral Drug Discovery 465<br /><i>Mélissanne de Wispelaere and Priscilla L. Yang</i></p> <p>15 Beyond Inhibition: Ligand-Based Pharmacological Exploration as a Strategy Toward New Targets and Modalities 491<br /><i>Milka Kostic and Lyn H. Jones</i></p> <p>Index 519 </p>